Covinnovations™ Makes Great Strides to Bring CovArrest™ to Market
Throughout the summer, CovInnovations™ made great strides toward bringing its revolutionary COVID-19 treatment, CovArrest™, to market.
CovArrest™ already has shown great potential to become the standard of care for those with late-stage COVID-19, thereby alleviating suffering and saving lives around the world.
CovInnovations™ has assembled a top-tier team of professionals who are capable of bringing this innovative product to market. CovInnovations™ is diligently working on advancing clinical trials, manufacturing facilities, and international relations in preparation for product sales, and distribution at home and abroad.
CovInnovations™ has retained a law firm with a global presence to assist with obtaining intellectual property protections and creating collaborations with others around the world. Also, the company is preparing its submittal of a Pre-IND letter.. The request is for FDA authorization to move forward with a phase III clinical study of CovArrest™
The company is preparing a written Clinical Trial Protocol that can be deployed internationally.
CovInnovations™ welcomes inquiry from those interested in being a part of this revolutionary product, as well as other technologies currently under development. Please visit our website for further information.
About CovArrest™
This new drug is composed of two current FDA-approved drugs that work synergistically to attack the same disease and are both metabolized by the same liver enzymes. One of the components of CovArrest™ showed significant success in a retrospective review completed in December 2020. This study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01). The treated group and the control group both received standard of care treatment as of 6/2020. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%. Those who did not survive appeared to experience a resurgence of viral replication or an insufficiently suppressed immune response, leading to the addition of the second component of CovArrest™. A subsequent cohort of 11 patients with the combined drug achieved 100% survival.
ABOUT CovInnovations™
CovInnovations™ creates technologies and solutions directly related to the COVID-19 pandemic. The company’s patent-pending treatments seek to create a new standard of care in the battle against this disease. CovInnovations™ products feature groundbreaking technologies that assess, diagnose and treat COVID-19 with the goal of integrating our world back to pre-pandemic times. The company was founded by Dr. Aury Nagy, M.D. FAANS, a neurosurgeon practicing in Las Vegas.
For further information, visit: www.covinnovations.com.
FORWARD LOOKING STATEMENT: Various statements contained in this presentation, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning the timing and success of strategies, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. These assumptions include, among others, our projections and expectations regarding: market trends litigation, our ability to create an opportunity with attractive current yields and upside. While we consider these expectations and assumptions to be somewhat reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements. We undertake no obligation to update any forward-looking statements to conform to actual results or changes in our expectations, unless required by applicable law.